July 25, 2013
FDA Public Meeting on REMS Standardization and Evaluation
ParagonRx will be presenting at FDA's Public Meeting: Standardizing and Evaluating Risk Evaluation and Mitigation Strategies
"The Food and Drug Administration (FDA) is announcing a 2-day public meeting to obtain input on issues and challenges associated with the standardization and assessment of risk evaluation and mitigation strategies (REMS) for drug and biological products. As part of the reauthorization of the Prescription Drug User Fee Act (PDUFA), FDA has committed to standardizing REMS to better integrate them into, and reduce their burden to, the existing and evolving health care system. As part of the PDUFA commitments, FDA will also seek to develop evidence-based methodologies for assessing the effectiveness of REMS.
To obtain input from stakeholders about REMS standardization and evaluation, FDA will hold a public meeting to give stakeholders, including health care providers, prescribers, patients, pharmacists, distributors, drug manufacturers, vendors, researchers, standards development organizations, and the public an opportunity to provide input on ways to standardize and assess REMS.
The docket for written comments will remain open indefinitely. However, submit comments no later than September 16th to be considered for FDA's report of its findings on standardization and identification of priority projects."
Silver Spring, MD 20993
To speak to a ParagonRx team member about an upcoming event
call 888.459.8080 or email email@example.com